DEA Greenlights Another Pot Importer—Comments Welcome!
Published Date: 9/24/2026
Notice
Summary
Fisher Clinical Services, Inc. wants to become an official importer of certain controlled substances like marijuana and its extracts. This affects companies involved in drug manufacturing and importation, who can comment or request a hearing by October 26, 2026. No direct costs are mentioned, but this move could impact how these substances enter the U.S. market.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Importer Application for Schedule I/II Drugs
On August 13, 2026, Fisher Clinical Services, Inc. applied to be registered to import specific controlled substances. The list includes Schedule I codes (Marihuana Extract 7350; Marihuana 7360; Tetrahydrocannabinols 7370; 3,4‑Methylenedioxy‑methamphetamine 7405; 5‑Methoxy‑N‑N‑Dimethyltryptamine 7431; Dimethyltryptamine 7435; Psilocybin 7437) and Schedule II codes (Methylphenidate 1724; Levorphanol 9220; Noroxymorphone 9668; Tapentadol 9780). The company plans to import the listed substances for clinical trials only.
No Import of Finished Dosage Forms
The DEA notice states that approval will not authorize the import of Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale. The registration is limited to the listed drug codes and to imports for clinical trials; no other activities for these codes are authorized.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-19539, Importer of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.
Cambridge Isotope Laboratories wants to become an official importer of certain controlled substances, including Gamma Hydroxybutyric Acid and Tetrahydrocannabinols. People and companies involved with these drugs can comment or ask for a hearing by October 26, 2026. This move could impact how these substances are imported and regulated, but no direct costs are mentioned yet.
Next: 2026-19541, Bulk Manufacturer of Controlled Substances Application: Eli-Elsohly Laboratories
Eli-Elsohly Laboratories wants to become a big-time maker of certain controlled substances like marijuana extracts and some strong medicines. People and companies involved with these drugs can share their thoughts or ask for a hearing by November 23, 2026. This move could impact drug supply and research, but no costs or changes to users are expected right now.